| Name | Title | Contact Details |
|---|
We are a global biotechnology company, specializing in discovering, developing, and delivering innovative therapies for the treatment of neurodegenerative, non-malignant hematologic and autoimmune diseases to patients worldwide. As a company, we are focused on cutting-edge science and medicines that address unmet patient needs and change the course of these devastating diseases. Founded in 1978, we are the world`s oldest independent biotechnology company and take pride in being known for pioneering the development of leading multiple sclerosis therapies. With approximately 7,000 employees worldwide, we are focused on better understanding the underlying biology of diseases so we can discover and deliver innovative treatments that make a real difference in the lives of patients. We also put great focus on being good corporate citizens. Our commitment to corporate citizenship extends to patient education and support programs, giving back to the communities in which we operate, promoting and advancing science education, and operating in a sustainable manner. These cultural imperatives are directly incorporated into our business activities.
Gritstone bio brings together a group of distinguished scientific founders and advisors, a highly experienced and diverse leadership team and a seasoned and successful board of directors to tackle fundamental challenges at the intersection of cancer genomics, immunotherapy and other precision therapy areas, specifically in COVID-19 and HIV. With our unique approach to immuno-oncology and infectious diseases, we seek to generate a therapeutic immune response by leveraging insights into the immune system`s ability to recognize and destroy diseased cells by targeting select antigens. We started with a focus on tumor-specific neoantigens and more recently extended our programs to include viral antigens displayed on the surface of virus-infected cells. The biology underlying immune system recognition of targets on the surface of abnormal cells is common to both anti-tumor and anti-viral immunity. Consequently, we believe that activating and directing the immune system to these targets could offer an important opportunity to extend the benefits of immunotherapy for more patients.
DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
20/20 GeneSystems Inc is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Numira is a specialty preclinical CRO that combines innovative technologies and expertise to provide unique solutions to a wide variety of preclinical drug discovery efforts. We support leading pharmaceutical, biotech, and medical device companies in the areas of discovery research and efficacy evaluation, offering services in the following areas - High-Resolution MicroCT Imaging, Image Analysis (microCT, MRI, ECG, histology data), Specialized Histology (GLP or non-GLP), 3D Oncology Cell Screening. Utilizing our patented imaging reagents and powerful 3D visualization and analytic tools, we provide images, metrics, and analyses that will allow definitive answers much more rapidly and accurately than ever before, saving your team valuable time and resources.